Aging is a complex process characterized by various phenotypic changes, including epigenetic modifications, inflammation, and metabolic dysregulation. Recent advancements in the field of epigenetics have led to the development of DNA methylation clocks, which estimate biological age and predict age-related outcomes based on DNA methylation profiles.
This study, conducted by Muthukumar et al., focuses on constructing a heterogeneous stacked ensemble survival model using DNA methylation data from the Framingham Heart Study. The researchers identified 190 CpG loci through elastic net Cox regression and created a survival prediction model by integrating five complementary survival models with a neural network meta-learner.
The model’s predictive power was evaluated in an external validation cohort, demonstrating strong performance in predicting all-cause mortality. Notably, the model’s performance exceeded that of PhenoAge and was statistically comparable to GrimAge. However, it is important to note that these estimates were derived from cohorts of European ancestry and validated in postmenopausal women aged 50-79 years, indicating that the applicability of these findings may be limited to similar demographic groups.
What this study does not show
This study does not establish clinical utility for the DNA methylation clock in predicting health outcomes beyond mortality, nor does it provide evidence for its effectiveness across diverse populations.
Evidence scorecard
- Analytic validity: established
- Clinical validity: partial
- Clinical utility: not established
The evidence is based on primary research involving human subjects.